Medical devices, healthcare technology and the business of care
PMA approval · P110020

COBAS 4800 BRAF V600 MUTATION TEST

Roche Molecular Systems, Inc. · Decision date Aug 17, 2011

FDA DECISIONP110020

What did the FDA approve?

FDA records P110020 as an original PMA application. The recorded decision is approval, dated Aug 17, 2011.

FDA approval order statement

APPROVAL FOR THE COBAS 4800 BRAF V600 MUTATION TEST. THIS DEVICE IS INDICATED FOR: THE COBAS 4800 BRAF V600 MUTATION TEST IS AN IN VITRO DIAGNOSTIC DEVICE INTENDED FOR THE QUALITATIVE DETECTION OF THE BRAF V600E MUTATION IN DNA EXTRACTED FROM FORMALIN-FIXED, PARAFFIN-EMBEDDED HUMAN MELANOMA TISSUE. THE COBAS 4800 BRAF V600 MUTATION TEST IS A REAL-TIME PCR TEST ON THE COBAS 4800 SYSTEM, AND IS INTENDED TO BE USED AS AN AID IN SELECTING MELANOMA PATIENTS WHOSE TUMORS CARRY THE BRAF V600E MUTATION FOR TREATMENT WITH VEMURAFENIB.
Regulatory pathway
Original PMA
Clinical specialty
Pathology
Decision date
Aug 17, 2011

FDA source record

Regulatory record facts

Identifier
P110020
Regulatory pathway
Premarket approval application
Product code
OWD
Decision code
APPR
Decision date
Aug 17, 2011
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Somatic gene mutation detection system.

Product code
OWD
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P110020 received

    Application receipt date recorded by FDA.

  2. P110020 · FDA decision

    APPR

  3. P110020/S045 · Related supplement

    cobas BRAF V600 Mutation Test

  4. P110020/S046 · Related supplement

    Roche cobas BRAF V600 Mutation Test

Timeline entries are records held by MedtechLedger for P110020. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P110020

Product / regulatory recordCompanyPathwayDecision dateSource
Roche Molecular Systems, Inc.PMA supplementOct 27, 2026FDA
Roche Molecular Systems, Inc.PMA supplementNov 4, 2026FDA

Explore the linked device profile

Other records with product code OWD

Product / regulatory recordCompanyPathwayDecision dateSource
RochePMA supplementNov 4, 2026FDA
Roche Molecular Systems, Inc.PMA supplementNov 4, 2026FDA
RochePMA supplementOct 27, 2026FDA
Roche Molecular Systems, Inc.PMA supplementOct 27, 2026FDA
Roche Molecular System, Inc.PMA supplementOct 27, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Roche Molecular Systems, Inc.

Headquarters
Not reported
Brand website
roche.com
FDA applicant address
4300 Hacienda Dr., Pleasanton, CA, 94588

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records